Optimizing the Diagnosis and Management of Dravet Syndrome: Recommendations From a North American Consensus Panel
- PMID: 28284397
- DOI: 10.1016/j.pediatrneurol.2017.01.025
Optimizing the Diagnosis and Management of Dravet Syndrome: Recommendations From a North American Consensus Panel
Abstract
Objectives: To establish standards for early, cost-effective, and accurate diagnosis; optimal therapies for seizures; and recommendations for evaluation and management of comorbidities for children and adults with Dravet syndrome, using a modified Delphi process.
Methods: An expert panel was convened comprising epileptologists with nationally recognized expertise in Dravet syndrome and parents of children with Dravet syndrome, whose experience and understanding was enhanced by their active roles in Dravet syndrome associations. Panelists were asked to base their responses to questions both on their clinical expertise and results of a literature review that was forwarded to each panelist. Three rounds of online questionnaires were conducted to identify areas of consensus and strength of that consensus, as well as areas of contention.
Results: The panel consisted of 13 physicians and five family members. Strong consensus was reached regarding typical clinical presentation of Dravet syndrome, range of electroencephalography and magnetic resonance imaging findings, need for genetic testing, critical information that should be conveyed to families at diagnosis, priorities for seizure control and typical degree of control, seizure triggers and recommendations for avoidance, first- and second-line therapies for seizures, requirement and indications for rescue therapy, specific recommendations for comorbidity screening, and need for family support. Consensus was not as strong regarding later therapies, including vagus nerve stimulation and callosotomy, and for specific therapies of associated comorbidities. Beyond the initial treatment with benzodiazepines and use of valproate, there was no consensus on the optimal in-hospital management of convulsive status epilepticus.
Conclusions: We were able to identify areas where there was strong consensus that we hope will (1) inform health care providers on optimal diagnosis and management of patients with Dravet syndrome, (2) support reimbursement from insurance companies for genetic testing and Dravet syndrome-specific therapies, and (3) improve quality of life for patients with Dravet syndrome and their families by avoidance of unnecessary testing and provision of an early accurate diagnosis allowing optimal selection of therapeutic strategies.
Keywords: Dravet syndrome; diagnosis; genetic testing; guidelines; questionnaire.
Copyright © 2017 Elsevier Inc. All rights reserved.
Similar articles
-
International consensus on diagnosis and management of Dravet syndrome.Epilepsia. 2022 Jul;63(7):1761-1777. doi: 10.1111/epi.17274. Epub 2022 May 12. Epilepsia. 2022. PMID: 35490361 Free PMC article.
-
Dravet Syndrome: Diagnosis and Long-Term Course.Can J Neurol Sci. 2016 Jun;43 Suppl 3:S3-8. doi: 10.1017/cjn.2016.243. Can J Neurol Sci. 2016. PMID: 27264139 Review.
-
Summary of recommendations for the management of infantile seizures: Task Force Report for the ILAE Commission of Pediatrics.Epilepsia. 2015 Aug;56(8):1185-97. doi: 10.1111/epi.13057. Epub 2015 Jun 30. Epilepsia. 2015. PMID: 26122601 Review.
-
Comorbidities and predictors of health-related quality of life in Dravet syndrome.Epilepsia. 2011 Aug;52(8):1476-82. doi: 10.1111/j.1528-1167.2011.03129.x. Epub 2011 Jun 10. Epilepsia. 2011. PMID: 21668444
-
Diagnosis, epilepsy treatment and supports for neurodevelopment in children with Dravet Syndrome: Caregiver reported experiences and needs.Epilepsy Behav. 2024 Feb;151:109603. doi: 10.1016/j.yebeh.2023.109603. Epub 2024 Jan 1. Epilepsy Behav. 2024. PMID: 38168600
Cited by
-
Cost Effectiveness of Adding Fenfluramine to Standard of Care for Patients with Dravet Syndrome in Sweden.Appl Health Econ Health Policy. 2024 Jul;22(4):543-554. doi: 10.1007/s40258-024-00886-0. Epub 2024 May 17. Appl Health Econ Health Policy. 2024. PMID: 38758509
-
Genetic exploration of Dravet syndrome: two case report.J Med Case Rep. 2024 Apr 23;18(1):215. doi: 10.1186/s13256-024-04514-2. J Med Case Rep. 2024. PMID: 38649973 Free PMC article.
-
Clinical and electrophysiological features of SCN8A variants causing episodic or chronic ataxia.EBioMedicine. 2023 Dec;98:104855. doi: 10.1016/j.ebiom.2023.104855. Epub 2023 Oct 28. EBioMedicine. 2023. PMID: 38251463 Free PMC article.
-
Clinical and Genetic Features of Dravet Syndrome: A Prime Example of the Role of Precision Medicine in Genetic Epilepsy.Int J Mol Sci. 2023 Dec 19;25(1):31. doi: 10.3390/ijms25010031. Int J Mol Sci. 2023. PMID: 38203200 Free PMC article. Review.
-
Neurologic orphan diseases: Emerging innovations and role for genetic treatments.World J Exp Med. 2023 Sep 20;13(4):59-74. doi: 10.5493/wjem.v13.i4.59. eCollection 2023 Sep 20. World J Exp Med. 2023. PMID: 37767543 Free PMC article. Review.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical